...
首页> 外文期刊>Hong Kong Journal of Paediatrics >A Historical Perspective of Cystic Fibrosis
【24h】

A Historical Perspective of Cystic Fibrosis

机译:囊性纤维化的历史展望

获取原文

摘要

Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which codes for a cyclic-AMP regulated chloride channel. Characteristic clinical features are recurrent pulmonary infections, exocrine pancreatic insufficiency and increased sweat electrolyte concentrations. CF was not clearly described in the medical literature until 1938. In this article the major discoveries and innovations that have been made since that time are reviewed and placed in historical context. They include the sweat test, comprehensive pulmonary and nutritional therapies, lung transplantation, discovery of the CFTR gene, and introduction of newborn screening. Therapies such as aerosolised mucolytic agents (dornase-a and hypertonic saline), aerosolised antibiotics (for example high-dose tobramycin and aztreonam) and CFTR modulator therapies such as ivacaftor have been developed in more recent years. These approaches have been associated with a significant increase in median life expectancy which reached 39.3 years in 2014.
机译:囊性纤维化(CF)是一种常染色体隐性遗传疾病,由囊性纤维化跨膜电导调节剂(CFTR)基因的突变引起,该基因编码环AMP调节的氯离子通道。临床特征是反复出现肺部感染,外分泌胰腺功能不全和汗液电解质浓度升高。直到1938年,医学文献中才对CF进行了明确的描述。本文对自那时以来的主要发现和创新进行了回顾,并将其置于历史背景下。其中包括汗液测试,全面的肺和营养疗法,肺移植,CFTR基因的发现以及新生儿筛查的介绍。近年来,已开发出诸如雾化粘液溶解剂(dornase-a和高渗盐水),雾化抗生素(例如大剂量妥布霉素和氨曲南)和CFTR调节剂疗法(如依伐卡托)等疗法。这些方法与预期寿命的中位数显着增加相关,该平均寿命在2014年达到39.3岁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号